AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10883158 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily i.v. glucosamine sulfate (GS) together with 800 mg chondroitin sulfate for 4 weeks
Number of subjects: 57
Study 10883158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 9085297 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Arithmetic (MA) followed by Cold Pressor Task (CP)
Number of subjects: 52
Study 9085297 — intervention group
Group type: COMPARATOR
Intervention: Cold Pressor Task (CP) followed by Mental Arithmetic (MA)
Number of subjects: 52
Study 8255520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (5 mg/kg b.i.d./day for 14 days)
Number of subjects: 32
Study 8255520 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ganciclovir)
Number of subjects: 32
Study 3987531 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg, retard form)
Number of subjects: 44
Study 3987531 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (160 mg)
Number of subjects: 44
Study 3987531 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (120 mg)
Number of subjects: 44
Study 31301210 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese pubertal youth
Number of subjects: 421
Study 31301210 — intervention group
Group type: COMPARATOR
Intervention: Obese adults
Number of subjects: 421
Study 31301210 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity
Number of subjects: 421
Study 31301210 — intervention group
Group type: COMPARATOR
Intervention: Systolic blood pressure (SBP) and high-density lipoprotein (HDL) cholesterol in adults
Number of subjects: 421
Study 31301210 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) and high-density lipoprotein (HDL) cholesterol in youth
Number of subjects: 421
Study 28340516 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein/Low Fat (55%C/25%P/20%F)
Number of subjects: 0
Study 28340516 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein/High Fat (35%C/25%P/40%F)
Number of subjects: 0
Study 28340516 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Protein/High Fat (45%C/15%P/40%F)
Number of subjects: 0
Study 28340516 — intervention group
Group type: COMPARATOR
Intervention: Low Carbohydrate (65%C/15%P/20%F)
Number of subjects: 0
Study 28340516 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest Carbohydrate Group
Number of subjects: 0
Study 25956480 — intervention group
Group type: EXPERIMENTAL
Intervention: CF+ group (with CF measuring catheter)
Number of subjects: 36
Study 25956480 — intervention group
Group type: COMPARATOR
Intervention: CF- group (without CF measuring catheter)
Number of subjects: 36
Study 22959318 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose in normal saline solution
Number of subjects: 188
Study 22959318 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 188
Study 22088178 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy formula
Number of subjects: 74
Study 22088178 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid formula
Number of subjects: 74
Study 22088178 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed formula
Number of subjects: 74
Study 22088178 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 22088178 — intervention group
Group type: EXPERIMENTAL
Intervention: All hypoallergenic formulae
Number of subjects: 74
Study 22088178 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid formula and extensively hydrolyzed formula
Number of subjects: 74
Study 19344615 — intervention group
Group type: EXPERIMENTAL
Intervention: Otoacoustic emission (OAE) testing
Number of subjects: 8
Study 19344615 — intervention group
Group type: COMPARATOR
Intervention: Audiometry
Number of subjects: 8
Study 16688058 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmeted motorcyclists
Number of subjects: 5328
Study 16688058 — intervention group
Group type: COMPARATOR
Intervention: Unhelmeted motorcyclists
Number of subjects: 5328
Study 16688058 — intervention group
Group type: COMPARATOR
Intervention: Cost comparison
Number of subjects: 5328
Study 16688058 — intervention group
Group type: COMPARATOR
Intervention: Overall economic burden
Number of subjects: 5328
Study 12630019 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 193
Study 12630019 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 193
Study 10711881 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery
Number of subjects: 46
Study 10711881 — intervention group
Group type: COMPARATOR
Intervention: Extracapsular cataract surgery
Number of subjects: 46
Study 10711881 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification and Extracapsular cataract surgery
Number of subjects: 46
Study 9360566 — intervention group
Group type: EXPERIMENTAL
Intervention: Premixed slurry of deferoxamine mesylate (DFO) and activated charcoal (AC) with 5 mg/kg ferrous sulfate and 8 g of DFO and 25 g of 20% AC
Number of subjects: 0
Study 9360566 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg ferrous sulfate alone
Number of subjects: 0
Study 9360566 — intervention group
Group type: COMPARATOR
Intervention: 5 mg/kg ferrous sulfate added to 25 g of 20% AC
Number of subjects: 0
Study 1492440 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 30
Study 1492440 — intervention group
Group type: COMPARATOR
Intervention: Conventional or no antiarrhythmic therapy
Number of subjects: 30
Study 4028957 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction in coping techniques
Number of subjects: 0
Study 4028957 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no instruction)
Number of subjects: 0
Study 31900475 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilapia skin xenograft dressing
Number of subjects: 62
Study 31900475 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine
Number of subjects: 62
Study 29429138 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 199
Study 29429138 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 199
Study 29429138 — intervention group
Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 199
Study 29429138 — intervention group
Group type: EXPERIMENTAL
Intervention: amisulpride
Number of subjects: 199
Study 29429138 — intervention group
Group type: EXPERIMENTAL
Intervention: aripiprazole
Number of subjects: 199
Study 29429138 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 199
Study 29429138 — intervention group
Group type: EXPERIMENTAL
Intervention: SCN5A (H558R)
Number of subjects: 199
Study 29429138 — intervention group
Group type: COMPARATOR
Intervention: KCNH2, KCNQ1, LOC10537879, LOC101927066, NOS1AP, NUBPL polymorphisms
Number of subjects: 199
Study 25529554 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated Grief Treatment (CGT)
Number of subjects: 69
Study 25529554 — intervention group
Group type: COMPARATOR
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 69
Study 24513787 — intervention group
Group type: COMPARATOR
Intervention: Interleukin‐2 receptor antagonists (daclizumab or basiliximab)
Number of subjects: 200
Study 24513787 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (RATG)
Number of subjects: 200
Study 23056520 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidform gel
Number of subjects: 36
Study 23056520 — intervention group
Group type: COMPARATOR
Intervention: HEC placebo gel
Number of subjects: 36
Study 20565956 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration exercises (1 hour, 3 times a week for 6 weeks)
Number of subjects: 40
Study 20565956 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy (1 hour, 3 times a week for 6 weeks)
Number of subjects: 40
Study 20565956 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration exercises
Number of subjects: 40
Study 20565956 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 40
Study 17548760 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based fitness curriculum
Number of subjects: 0
Study 15897266 — intervention group
Group type: EXPERIMENTAL
Intervention: Large pictograms
Number of subjects: 227
Study 15897266 — intervention group
Group type: COMPARATOR
Intervention: Small pictograms
Number of subjects: 227
Study 15897266 — intervention group
Group type: EXPERIMENTAL
Intervention: Second presentation of pictograms
Number of subjects: 227
Study 12784968 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression
Number of subjects: 0
Study 12784968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinal logit regression model
Number of subjects: 0
Study 9607246 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education (HE) from family doctor
Number of subjects: 110
Study 9607246 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) of 55 patients who received HE from their family doctor
Number of subjects: 110
Study 9778551 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) combined with recombinant tissue plasminogen activator (rTPA) or streptokinase (STK)
Number of subjects: 112
Study 9778551 — intervention group
Group type: COMPARATOR
Intervention: Control group (rTPA or STK alone)
Number of subjects: 112
Study 9778551 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO)
Number of subjects: 112
Study 1927911 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine 10 mg once daily
Number of subjects: 178
Study 1927911 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine 10 mg twice daily
Number of subjects: 178
Study 1927911 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine 20 mg once daily
Number of subjects: 178
Study 1927911 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 178
Study 6752580 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Indicator (SI) technique for estimating extravascular thermal volume (EVTV)
Number of subjects: 147
Study 30649058 — intervention group
Group type: EXPERIMENTAL
Intervention: VACS Index 2.0 with albumin, white blood count, and BMI
Number of subjects: 28390
Study 30649058 — intervention group
Group type: COMPARATOR
Intervention: VACS Index 1.0
Number of subjects: 28390
Study 29251433 — intervention group
Group type: COMPARATOR
Intervention: Timely linkage-to-care and ART initiation (TLA)
Number of subjects: 705
Study 29251433 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior familiarity with Community HIV-care Providers (CHiPs)
Number of subjects: 705
Study 29251433 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of clinics being overcrowded
Number of subjects: 705
Study 29251433 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconvenient clinic opening hours
Number of subjects: 705
Study 29251433 — intervention group
Group type: EXPERIMENTAL
Intervention: Feelings of shame about having HIV
Number of subjects: 705
Study 29251433 — intervention group
Group type: EXPERIMENTAL
Intervention: Not feeling ready to seek treatment
Number of subjects: 705
Study 29251433 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferring to wait until feeling sick
Number of subjects: 705
Study 29251433 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of self-reported lifetime sexual partners
Number of subjects: 705
Study 29251433 — intervention group
Group type: EXPERIMENTAL
Intervention: Having HIV-positive partners on ART
Number of subjects: 705
Study 23343932 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent bovine‐human reassortant rotavirus vaccine
Number of subjects: 558
Study 22406729 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional composite resin with conventional etchant
Number of subjects: 300
Study 22406729 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer resin adhesive
Number of subjects: 300
Study 22406729 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-changing composite resin with conventional etchant
Number of subjects: 300
Study 22406729 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-changing composite resin with self-etch primer
Number of subjects: 300
Study 19101754 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral 1 mg minodronate for 24 months
Number of subjects: 704
Study 19101754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study 17336698 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 2314
Study 15258682 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg bid
Number of subjects: 28
Study 15258682 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine 250 mg bid
Number of subjects: 28
Study 11528141 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg twice a day, adjusted weekly until a minimum decrease of 20% in cardiac frequency achieved)
Number of subjects: 0
Study 11528141 — intervention group
Group type: COMPARATOR
Intervention: Control group (no beta-adrenergic blockade)
Number of subjects: 0
Study 9401836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (2.5, 3.5, or 6.0 mg/kg) via jet injector
Number of subjects: 30
Study 9401836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (dosage based on mg/m2 body surface area or mg/kg body weight)
Number of subjects: 30
Study 9401836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 30
Study 8438810 — intervention group
Group type: EXPERIMENTAL
Intervention: DT-aP vaccine
Number of subjects: 246
Study 8438810 — intervention group
Group type: COMPARATOR
Intervention: WC-DTP vaccine
Number of subjects: 246
Study 2979214 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg o.m. for 14 days
Number of subjects: 16
Study 2979214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29803836 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement for a maximum of 2 weeks
Number of subjects: 65
Study 29803836 — intervention group
Group type: COMPARATOR
Intervention: Balloon dilatation
Number of subjects: 65
Study 26209256 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene fortified synbiotic food
Number of subjects: 51
Study 26209256 — intervention group
Group type: COMPARATOR
Intervention: Control food
Number of subjects: 51
Study 25491556 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and volar angle‐stable plate osteosynthesis (ORIF)
Number of subjects: 185
Study 25491556 — intervention group
Group type: COMPARATOR
Intervention: Closed reposition and casting
Number of subjects: 185
Study 22717925 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (Cypher; Cordis, Miami Lakes, FL, USA; n=20 patients)
Number of subjects: 40
Study 22717925 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (Driver; Medtronic, Santa Clara, CA, USA; n=20 patients)
Number of subjects: 40
Study 20130836 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg morphine in 20 ml saline
Number of subjects: 60
Study 20130836 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 0.25% bupivacaine
Number of subjects: 60
Study 20130836 — intervention group
Group type: COMPARATOR
Intervention: 20 ml saline (placebo)
Number of subjects: 60
Study 18759644 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (APZ) at a mean dose of 6.7 mg/day
Number of subjects: 23
Study 18759644 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (APZ)
Number of subjects: 23
Study 15981071 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drainage of the cavity
Number of subjects: 50
Study 15981071 — intervention group
Group type: COMPARATOR
Intervention: No suction drainage of the cavity
Number of subjects: 50
Study 12679354 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 6 mg/day
Number of subjects: 30
Study 12679354 — intervention group
Group type: COMPARATOR
Intervention: discontinuation of rhGH therapy
Number of subjects: 30
Study 10482213 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy supportive presentation style ("It's Your Choice")
Number of subjects: 400
Study 10482213 — intervention group
Group type: COMPARATOR
Intervention: Non-autonomy supportive presentation style
Number of subjects: 400
Study 8960947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oils (12 capsules, 3.6 g/day of omega 3)
Number of subjects: 40
Study 8960947 — intervention group
Group type: COMPARATOR
Intervention: Soya oil (12 capsules per day)
Number of subjects: 40
Study 2069440 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 90
Study 2069440 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study 6622502 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg theophylline tablet taken as 2 halves
Number of subjects: 10
Study 6622502 — intervention group
Group type: COMPARATOR
Intervention: 400 mg theophylline tablet taken whole
Number of subjects: 10
Study 31831255 — intervention group
Group type: COMPARATOR
Intervention: CD40 blockade (Iscalimab)
Number of subjects: 0
Study 31831255 — intervention group
Group type: COMPARATOR
Intervention: B-cell activating factor receptor (Ianalumab) inhibition
Number of subjects: 0
Study 31831255 — intervention group
Group type: COMPARATOR
Intervention: Cathepsin-S (Petesicatib)
Number of subjects: 0
Study 31831255 — intervention group
Group type: COMPARATOR
Intervention: Inducible costimulator of T cells ligand (prezalumab)
Number of subjects: 0
Study 31831255 — intervention group
Group type: COMPARATOR
Intervention: Lymphotoxin beta receptor (baminercept)
Number of subjects: 0
Study 31831255 — intervention group
Group type: COMPARATOR
Intervention: Other kinase inhibitors
Number of subjects: 0
Study 31831255 — intervention group
Group type: COMPARATOR
Intervention: Transmembrane activator and calcium-modulator and cytophilin ligand interactor TACI fusion protein (RC18)
Number of subjects: 0
Study 31831255 — intervention group
Group type: COMPARATOR
Intervention: Low dose recombinant interleukin-2 to expand T-regulatory cells
Number of subjects: 0
Study 30870970 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon (2 cups daily)
Number of subjects: 33
Study 30870970 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric low-fat cookies
Number of subjects: 33
Study 29119319 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory stimulation with anise or cinnamon
Number of subjects: 50
Study 29119319 — intervention group
Group type: COMPARATOR
Intervention: Odorless stimulation
Number of subjects: 50
Study 29119319 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory stimulation (only more mature newborns, n=39)
Number of subjects: 50
Study 26720751 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritis intervention group
Number of subjects: 300
Study 26720751 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 300
Study 25123917 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP-neurofeedback
Number of subjects: 144
Study 25123917 — intervention group
Group type: COMPARATOR
Intervention: EMG-biofeedback (active control)
Number of subjects: 144
Study 21996047 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 150 mg/d
Number of subjects: 51
Study 21996047 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 60 mg/d
Number of subjects: 51
Study 21996047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 19188529 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-month course of nurse-delivered telephone-based collaborative care supervised by a psychiatrist and primary care expert
Number of subjects: 450
Study 19188529 — intervention group
Group type: COMPARATOR
Intervention: usual care by their physicians
Number of subjects: 450
Study 17874269 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow-up
Number of subjects: 2923
Study 17874269 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular surveillance with serum carcinoembryonic antigen
Number of subjects: 2923
Study 17874269 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 2923
Study 17874269 — intervention group
Group type: COMPARATOR
Intervention: Less intensive follow-up
Number of subjects: 2923
Study 15005784 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of episiotomy only for fetal indications (group a)
Number of subjects: 146
Study 15005784 — intervention group
Group type: COMPARATOR
Intervention: Use of episiotomy in addition at a tear presumed to be imminent (group b)
Number of subjects: 146
Study 12174061 — intervention group
Group type: EXPERIMENTAL
Intervention: Graftskin therapy with aggressive debridement and standardized wound care
Number of subjects: 17
Study 12174061 — intervention group
Group type: COMPARATOR
Intervention: Standardized wound care alone with aggressive debridement
Number of subjects: 17
Study 9714263 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine, 37.5 mg twice daily (increased to 75 mg twice daily after 3 weeks if poor response)
Number of subjects: 382
Study 9714263 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine, 20 mg once daily (increased to 20 mg twice daily after 3 weeks if poor response)
Number of subjects: 382
Study 7806723 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 verbal process components
Number of subjects: 39
Study 7806723 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 standard symptom intensity measures
Number of subjects: 39
Study 2617209 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of amoxycillin
Number of subjects: 12
Study 2617209 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of amoxycillin combined with 1 g of probenecid
Number of subjects: 12
Study 1150128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine (Cypro)
Number of subjects: 23
Study 1150128 — intervention group
Group type: EXPERIMENTAL
Intervention: Methysergide (Methyl)
Number of subjects: 23
Study 1150128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 1150128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cypro and Methy
Number of subjects: 23
Study 1150128 — intervention group
Group type: COMPARATOR
Intervention: Cypro, Methy, and Placebo
Number of subjects: 23
Study 1150128 — intervention group
Group type: COMPARATOR
Intervention: Cypro (normal and acromegalic subjects) and Methy (normal subjects)
Number of subjects: 23
Study 30914493 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure extubation
Number of subjects: 240